Brinker Capital Investments, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Brinker Capital Investments, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Jul 31, 2025	SELL	$19.53 - $25.74 $46,715 - $61,570	-2,392 Reduced 18.1%	10,820 $262,000
Q3 2024 Jul 31, 2025	SELL	$15.19 - $21.35 $1,215 - $1,708	-80 Reduced 0.6%	13,212 $262,000
Q2 2024 Jul 31, 2025	SELL	$14.68 - $16.92 $2,789 - $3,214	-190 Reduced 1.41%	13,292 $205,000
Q1 2024 Jul 31, 2025	BUY	$13.18 - $17.11 $42,162 - $54,734	3,199 Added 31.11%	13,482 $214,000
Q4 2023 Jul 31, 2025	SELL	$11.78 - $17.29 $31,158 - $45,732	-2,645 Reduced 20.46%	10,283 $172,000
Q3 2023 Jul 31, 2025	SELL	$11.69 - $15.02 $10,357 - $13,307	-886 Reduced 6.41%	12,928 $151,000
Q2 2023 Jul 31, 2025	BUY	$11.5 - $18.08 $36,282 - $57,042	3,155 Added 29.6%	13,814 $185,000
Q1 2023 Jul 31, 2025	BUY	$14.34 - $21.05 $152,850 - $224,371	10,659 New	10,659 $176,000

386

103M

277K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.11B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Brinker Capital Investments, LLC with notifications on news.